What is Codex BioSolutions?
Codex BioSolutions, formerly known as Dexorgen, Inc., operates as a specialized biotechnology entity headquartered in Maryland. The firm is primarily recognized for its high-throughput solutions designed to assist scientists in navigating complex drug discovery challenges. Central to its technological portfolio is the patented ACTOne platform, which utilizes phosphodiesterase (PDE) and G-protein coupled receptor (GPCR) cell lines to enable precise compound screening within live cell environments. Beyond its core screening capabilities, the company provides comprehensive assay development services and produces unique biochemical kits and specialty dyes, serving as a critical partner for pharmaceutical organizations and academic research institutions globally.
How much funding has Codex BioSolutions raised?
Codex BioSolutions has raised a total of $42K across 1 funding round:
Debt
$42K
Debt (2021): $42K with participation from PPP
Key Investors in Codex BioSolutions
PPP
Public-Private Partnership
What's next for Codex BioSolutions?
With the successful closure of this Series B/C stage financing, Codex BioSolutions is poised to scale its operational capacity and deepen its collaborative efforts with major pharmaceutical players. The strategic deployment of these funds will likely focus on expanding the reach of its ACTOne platform and enhancing its suite of biochemical assay tools. As the drug discovery market continues to demand more efficient, high-fidelity screening methodologies, Codex BioSolutions is strategically aligned to capture increased market share by addressing the technical bottlenecks inherent in modern therapeutic development. Future growth will likely be driven by continued investment in R&D and the potential for new strategic partnerships that leverage its unique cell-based screening expertise.
See full Codex BioSolutions company page
